Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CHINA INTERNATIONAL CAPITAL CORPORATION LIMITED

(3908)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Health Care In The Year Of The Ox: Navigating China's Dynamic M&A Market

07/26/2021 | 04:10pm EDT

Despite the challenges presented by the pandemic, the Chinese health care sector continues to be fertile ground for both inbound and outbound M&A activity. To explore the nuances of that market, Winston & Strawn brought together health care leaders and investors for a panel discussion during Winston's 2021 Health Care and Life Sciences Summit. The panel included James Jiang, head of the corporate practice at YuandaWinston (the alliance of Winston & Strawn and China's Yuanda Law Firm); Bagrin Angelov, Executive Director and Head of China Cross-Border M&A, China International Capital Corporation Limited (CICC), and Richard Lu, Managing Director, SDIC Fund Management Co., Ltd. Highlights of the discussion included the following:

MORE CAPITAL FOR FEWER FIRMS

The pandemic's disruptions led the number of new foreign invested enterprises (FIEs) in China to decrease by 21 percent in 2020. However, the total amount of capital invested in those firms increased by 113 percent. Within the technology sector (which includes life sciences), the capital influx is even stronger, increasing more than 20-fold during 2020 compared with 2019. It is also worth noting that the number of new FIEs is slowly rebounding: While 35 percent fewer FIEs were registered in May 2020 vs. the previous year, by November, the gap narrowed to 11 percent.

CAPITAL FLOWS REACH PARITY

China cross-border investment has dropped by 70 percent or more since its peak in 2015-2016, when it represented approximately 30 percent of all Chinese M&A activity. But at that peak, 90 percent of capital was money flowing out of China. Since then, inbound investment has increased steadily and now roughly matches outbound numbers. This development reflects a more stable environment for foreign investors, including more stringent IP protection and enforcement, and in health care, a streamlined and accelerated drug approval process.

IP REFORM WITH TEETH

Foreign investors have taken comfort in the amendments China made last year to its patent regime, bringing its IP regulations more in line with those of the United States and allowing for corporate governance beyond joint ventures. Just as important as the regulations themselves is the establishment of a judicial infrastructure, including specialized IP courts racing to build a body of case law. The changes are trickling down to local courts as well, which are not just granting sizable awards for infringement, but for the first time, awarding punitive damages. However, the particular technical complexities of adjudicating life sciences make for extended resolution times.

DIGITAL IS AT THE CENTER

The vast potential of digital health has made health care the hottest sector of Chinese M&A. While a robust framework is already in place that allows patients to do everything from choose a clinic to receive test results on their devices, opportunities for further cross-sector integration abound: Witness, for example, the acquisition of drugstore chains by the Chinese internet giants and the acceleration of the licensing of online hospitals.

OUTBOUND SHOPPING LISTS ARE LONGER

Both Chinese funds and strategics are broadening their view when looking for deals outside of China. The longstanding focus on medtech has moved upstream from devices such as scanners to the sensors and chips that power them. In addition, China's growing lifestyle brands are looking to expand their presence in dietary supplements, beauty, and pet health. (Foreign investors are attracted to China's consumer market as well—but understanding the nuances of the local market remains a significant hurdle.)

INNOVATION IS A TWOWAY STREET

The evolution of China's IP environment goes beyond regulation and enforcement. Foreign companies are no longer looking to China primarily for materials, manufacturing, and market access; Shanghai, Beijing, Hong Kong, and Shenzhen are vibrant innovation hubs in their own right. One sign of this can be seen among China's health care AI startups, where 21 percent of financing rounds in 2020 were Series D and above, up from 7 percent in 2019.

AS VALUATIONS RISE, CROSS- BORDER ALLIANCES GROW

The attractiveness of China's health care market has led to an appreciable increase in valuations, even if 80 percent of China's health care companies are pre-revenue. This dynamic has led foreign investors to partner with Chinese counterparts to increase the ability of those foreign investors to seize early-stage opportunities quickly.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mr James Jiang
Winston & Strawn LLP
35 West Wacker Drive
Chicago
IL 60601
UNITED STATES
Tel: 3125585600
Fax: 3125585700
E-mail: awisinski@winston.com
URL: www.winston.com

© Mondaq Ltd, 2021 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

All news about CHINA INTERNATIONAL CAPITAL CORPORATION LIMITED
09/16SHIMAO : Files for Singapore Listing of Bonds Worth over $1 Billion
MT
09/15GF Financial Holdings Files for Singapore Listing of $300 Million Bonds
MT
09/09DONGYUE : Raises Nearly $426 Million From Private Placement; Shares Slump 6%
MT
09/09TENCENT : Backed Nio to Sell Up to $2 Billion Shares; Shares Tank 6%
MT
09/05Hanwei Electronics Raises Nearly $92 Million in Private Placement; Shares Fal..
MT
09/05Chinese Hotpot Chain Operator Laowang Files for Hong Kong IPO
MT
09/03TENCENT : Hong Kong shares end lower ahead of key U.S. data
RE
09/03Xuchang General Investment Files for Singapore Listing of $53 Million Bonds
MT
08/31DONGYUE : Seeks Nearly $426 Million in Private Placement
MT
08/30Chinese Pub Operator Helens Launches Up to $358 Million Hong Kong IPO
MT
More news
Analyst Recommendations on CHINA INTERNATIONAL CAPITAL CORPORATION LIMITED
More recommendations
Financials
Sales 2021 36 199 M 5 599 M 5 599 M
Net income 2021 9 228 M 1 427 M 1 427 M
Net Debt 2021 107 B 16 572 M 16 572 M
P/E ratio 2021 9,12x
Yield 2021 1,57%
Capitalization 199 B 30 849 M 30 847 M
EV / Sales 2021 8,47x
EV / Sales 2022 8,97x
Nbr of Employees 12 744
Free-Float 77,4%
Chart CHINA INTERNATIONAL CAPITAL CORPORATION LIMITED
Duration : Period :
China International Capital Corporation Limited Technical Analysis Chart | 3908 | CNE100002359 | MarketScreener
Technical analysis trends CHINA INTERNATIONAL CAPITAL CORPORATION LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 17,53 CNY
Average target price 21,98 CNY
Spread / Average Target 25,4%
EPS Revisions
Managers and Directors
Zhao Hui Huang CEO, Executive Director & Compliance Officer
Aiming Huang President
King Fung Wong Chief Financial Officer
Tao Gao Chairman-Supervisory Board
Ru Jun Shen Non-Executive Chairman
Sector and Competitors